Markus Hoffmann

Dr. Markus Hoffmann

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Cell
Verified
Journal Article
Open access
MHMarkus Hoffmann
Markus Hoffmann
HKHannah Kleine-Weber
Hannah Kleine-Weber
SSSimon Schroeder
Simon Schroeder
NKNadine Krüger
Nadine Krüger
THTanja Herrler
Tanja Herrler
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann
The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.

1 May 2020 in Molecular Cell
Verified
Journal Article
Closed access
MHMarkus Hoffmann
Markus Hoffmann
HKHannah Kleine-Weber
Hannah Kleine-Weber
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann

1 April 2021 in Cell
Verified
Journal Article
Closed access
MHMarkus Hoffmann
Markus Hoffmann
PAPrerna Arora
Prerna Arora
RGRüdiger Groß
Rüdiger Groß
ASAlina Seidel
Alina Seidel
BHBojan F. Hörnich
Bojan F. Hörnich
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann

24 December 2021 in Cell
Verified
Journal Article
Closed access
MHMarkus Hoffmann
Markus Hoffmann
NKNadine Krüger
Nadine Krüger
SSSebastian Schulz
Sebastian Schulz
ACAnne Cossmann
Anne Cossmann
CRCheila Rocha
Cheila Rocha
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann

14 July 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JBJoana Barros-Martins
Joana Barros-Martins
SHSwantje I. Hammerschmidt
Swantje I. Hammerschmidt
ACAnne Cossmann
Anne Cossmann
IOIvan Odak
Ivan Odak
MSMetodi Stankov
Metodi Stankov
GBGeorg BEHRENS
Georg BEHRENS
Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School’s COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer’s BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.

21 May 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MHMarkus Hoffmann
Markus Hoffmann
SSSimon Schroeder
Simon Schroeder
HKHannah Kleine-Weber
Hannah Kleine-Weber
MMMarcel A. Müller
Marcel A. Müller
CDChristian Drosten
Christian Drosten
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann
The currently unfolding coronavirus pandemic threatens health systems and economies worldwide.…